FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE

被引：0
|
作者：
Daneshmand, Siamak
van der Heijden, Michiel S.
Jacob, Joseph M.
Necchi, Andrea
Xylinas, Evanguelos
Morris, David S.
Spiegelhalder, Philip
Zainfeld, Daniel
Kang, Taek Won
Matulay, Justin T.
Belkoff, Laurence H.
Decaestecker, Karel
Arentsen, Harm
Hampras, Shalaka
Jin, Shu
Cutie, Christopher J.
Sweiti, Hussein
Stromberg, Katherine
Martin, Jason
Simone, Giuseppe
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
LBA02-03
引用
收藏
页码：E1187 / E1187
页数：1
相关论文
共 50 条
  • [1] SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guerin in patients with BCG-naive high-risk non-muscle-invasive bladder cancer
    Catto, J. W. F.
    Necchi, A.
    Powles, T.
    Guerrero-Ramos, F.
    Simone, G.
    Shore, N.
    Salinas, J. S.
    Merseburger, A. S.
    Roumiguie, M.
    Hiroshi, K.
    Morris, D. M.
    Qiang, W.
    Korkes, F.
    Hasan, M.
    Jin, S.
    Maffeo, J.
    Hammond, C.
    Sweiti, H.
    Somer, R. S.
    Chang, S. S.
    EUROPEAN UROLOGY, 2024, 85 : S1505 - S1505
  • [2] Results from SunRISe-1 in patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 monotherapy
    Necchi, A.
    Jacob, J. M.
    Daneshmand, S.
    Simone, G.
    Xylinas, E.
    Morris, D. S.
    Spiegelhalder, P.
    Zainfeld, D.
    Kang, T. W.
    Matulay, J. T.
    Belkoff, L. H.
    Decaestecker, K.
    Arentsen, H.
    Hampras, S.
    Cutie, C. J.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shulka, A.
    Van Der Heijden, M. S.
    EUROPEAN UROLOGY, 2024, 85 : S1508 - S1509
  • [3] SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin who are ineligible for or decline radical cystectomy.
    Van der Heijden, Michiel Simon
    Cutie, Christopher
    Hampras, Shalaka
    Indoria, Charu
    Stewart, Rachel
    Acharya, Milin
    Stromberg, Katherine
    Li, Xiang
    Beeharry, Neil
    Maffeo, John
    Jacob, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
    Necchi, A.
    Catto, J. W. F.
    Powles, T. B.
    Guerrero-Ramos, F.
    Simone, G.
    Shore, N. D.
    Salinas, J.
    Merseburger, A. S.
    Roumiguie, M.
    Kitamura, H.
    Morris, D.
    Wei, Q.
    Korkes, F.
    Hasan, M.
    Jin, S.
    Maffeo, J.
    Hammond, C.
    Sweiti, H.
    Somer, R.
    Chang, S. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1224 - S1224
  • [5] SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guerin who are ineligible for or elected not to undergo radical cystectomy
    van der Heijden, M. S.
    Cutie, C.
    Acharya, M.
    Stromberg, K.
    Li, X.
    Beeharry, N.
    Stewart, R.
    Maffeo, J.
    Indoria, C.
    Levin, W.
    Jacob, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S723 - S724
  • [6] SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUERIN (BCG)UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1
    Siamak, Daneshmand
    Daniel, Zainfeld
    Christopher, Pieczonka
    Giuseppe, Simone
    Michiel, S. van der Heijden
    Martin, Bogemann
    David, S. Morris
    Philipp, Spiegelhalder
    Laurence, H. Belkoff
    Karel, Decaestecker
    Harm, Arentsen
    Shalaka, Hampras
    Christopher, J. Cutie
    Hussein, Sweiti
    Katharine, Stromberg
    Jason, Martin
    Abhijit, Shukla
    Joseph, M. Jacob
    Evanguelos, Xylinas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [7] TAR-200+/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette- Guerin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
    van der Heijden, M. S.
    Simone, G.
    Boegemann, M.
    Xylinas, E.
    Roumiguie, M.
    Guerrero-Ramos, F.
    Necchi, A.
    Daneshmand, S.
    Van Praet, C.
    Spiegelhalder, P.
    Decaestecker, K.
    Arentsen, H.
    Zainfeld, D.
    Hampras, S.
    Cutie, C. J.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shukla, A.
    Jacob, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1272 - 1273
  • [8] SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy.
    Psutka, Sarah P.
    Cutie, Christopher
    Bhanvadia, Sumeet Kaur
    Keegan, Kirk A.
    Crist, Wendy
    Tian, Shaozhou Ken
    Maffeo, John
    Raybold, Bradley
    Kashmer, Marietta
    Hasan, Mohamad
    Li, Xiang
    Beeharry, Neil
    Thomas, Shibu
    Tian, Hui
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] First-line Maintenance Therapy in Adult Patients with BCG-naive High-risk - non-muscle-invasive Bladder Cancer Open-label, multicenter, randomized Phase 3 Study to evaluate the Efficacy and Safety of TAR-200 in combination with Cetrelimab versus TAR-200 Monotherapy versus intravesical Bacillus Calmette-Guerin (BCG) in Patients with BCG-naive High-risk non-muscle-invasive Bladder Cancer (HR-NMIBC) - SUNRISE-3-AB 85/23 of AUO
    Rexer, H.
    Stenzl, A.
    Ohlmann, C. -H.
    UROLOGIE, 2024, 63 (01): : 135 - 136
  • [10] Results from SunRISe-1 in patients (Pts) with bacillus CalmetteeGuerin (BCG)-unresponsive high-risk non emuscle-invasive bladder cancer (HR NMIBC) receiving TAR200 monotherapy
    Necchi, A.
    Jacob, J. M.
    Daneshmand, S.
    Simone, G.
    Xylinas, E.
    Morris, D.
    Spiegelhalder, P.
    Zainfeld, D.
    Kang, T. W.
    Matulay, J. T.
    Belkoff, L.
    Decaestecker, K.
    Arentsen, H.
    Hampras, S.
    Cutie, C.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shukla, A.
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1343 - S1344
12345